"Mesenchymal Stem Cells May Reduce Complications in Heart Failure Patients with LVAD" - Marie Benz
Annetine Gelijns, PhD, JD, professor of population health science and policy at the Icahn School of Medicine at Mount Sinai and Alan Moskowitz, MD, professor of medicine and population health science and policy at the Icahn School of Medicine at Mount Sinai discuss their recent study of patients with heart failure. “Implantable LVADs significantly improve the survival and quality of life of advanced heart failure patients. However, these devices are associated with substantial adverse events, including infection and thromboembolic events.” The main findings of the study indicated the mean proportion of successful temporary weans from LVAD support were not significantly different between MPC and control patients. Recommendations for future research indicates a need to conduct a confirmatory trial that determines, with precision, the efficacy of Mesenchymal precursor cells therapy in reducing GI bleeding in LVAD patients, as well as mechanistic studies to identify the biological mechanisms associated with this effect.
— Annetine C. Gelijns, PhD, JD, System Chair, Professor, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai
— Alan J. Moskowitz, MD, Professor, Medicine, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai